Full-Time

Operations Coordinator

Multiple Teams

Posted on 10/3/2025

Cencora

Cencora

10,001+ employees

Global pharmaceutical distribution and services provider

No salary listed

Remote in Canada

Remote

Category
Operations & Logistics (1)
Required Skills
Inventory Management
Marketing
Requirements
  • Bachelor degree, Business, Science or Arts
  • 3-5 years total combined experience in marketing, client services and/or account management
  • Strong communication skills both written and verbal
  • Ability to prioritize and multi-task
  • Ability to apply critical thinking skills in order to solution problems
  • Bilingualism in French and English required
  • Highly organized with strong attention to detail
Responsibilities
  • Coordinates projects with service providers (i.e. printers, creative partner, fulfillment partner) to ensure client satisfaction with card service and delivery
  • Liaises with adjudication partner on program set-ups and reporting
  • Participates in client meetings, as required
  • Develops work back schedules for card program initiatives
  • Acts as liaison between CSL and the client on material production
  • Assists with client reviews and approval processes (i.e. PromoMats ZincMaps, Veeva Vault) and Pharmaceutical Advertising Advisory Board (PAAB) submissions
  • Works with CSL leadership team, Innomar Marketing, and outside agencies to develop promotions and promotional materials to increase card uptake and return on investment
  • Develops client marketing materials to support card programs (HCP faxes, call scripts, detail aids, brochures)
  • Proof-reads materials prior to print production/delivery
  • Acts as point person for CSL Reporting Portal additions
  • Responsible for RxHelp Admin portal and RxHelp site maintenance, program and logo additions, coordinating site updates and changes with Innomar IT
  • Coordinates the preparation and delivery of RxHelp card and other materials to customers
  • Coordinates delivery of materials to client sales reps
  • Works with our adjudication partner company to ensure adequate inventory is available for all fulfillment
  • Develops and maintains strong relationships with major customers and partners
  • Interacts with Finance and clients on invoicing and Purchase Order issues
  • Manages all French translations for program materials
  • Supports the development of RFP requests and liaises with internal staff (NBD) as needed to deliver client proposals
  • Acts as point person on client AE/PV training (annual for all clients), completes and submits Adverse Event Reports
  • Sends monthly program reports to clients
  • Consistently maintains high corporate profile with key customers and strategic business partners
  • Works closely with the rest of the CSL team to gather feedback from customers on requirements and business needs
  • Works with the CSL Team to resolve complex business issues or concerns
  • Provides pre and post-sales support service, ensuring optimum customer satisfaction and maximizing business benefits
  • Interfaces with suppliers to attain and negotiate quotes for creative and printing services
  • Provides assistance and support with the preparation of proposals (reviews and edits copy written by other members of the CSL team)
  • Liaises with the Account leads to maintain maximum levels of account support
  • Acts as a point of contact for technical queries, HCP and patient inquiries (through [email protected])
  • Handles various administrative tasks for the CSL team (i.e. Fedex shipments, rep mailing requests)
Desired Qualifications
  • Extensive knowledge of the Pharmaceutical Industry, specialty programs and ideally a good understanding of the PAAB Code
  • Strong writing and editing capabilities
  • Ability to work on many projects at once with various individuals
  • Minimal travel required
  • Strong Knowledge of Microsoft Word, Excel, PowerPoint and other Office Programs
  • Knowledge of graphic illustrator or Photoshop an asset

Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.

Company Size

10,001+

Company Stage

IPO

Headquarters

Pennsylvania

Founded

1907

Simplify Jobs

Simplify's Take

What believers are saying

  • OneOncology $5B acquisition completed December 2025 boosts specialty oncology leadership.
  • EyeSouth retina business $1.1B deal expands Retina Consultants, accretive to EPS post-closure.
  • FY2026 EPS guidance raised to $17.65–$17.90 despite revenue headwinds from biosimilars.

What critics are saying

  • Frank R. Cruz investigation triggers shareholder lawsuits after May 6, 2026 Q2 revenue miss.
  • McKesson and Cardinal Health seize specialty drug share via aggressive GLP-1 pricing.
  • Inflation Reduction Act price cuts compress margins beyond $2B Q2 2026 headwind.

What makes Cencora unique

  • Cencora rebranded from AmerisourceBergen in August 2023, trading as COR on NYSE.
  • Cencora operates 1,400 locations across 50+ countries for global pharmaceutical distribution.
  • Cencora uniquely serves human and animal health with specialty pharmacy and MSO platforms.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Parental Leave

Adoption Assistance

Infertility Coverage

Family Planning Benefits

Behavioral Health Solutions

Professional Development Budget

Training Programs

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Mar 23rd, 2026
Cencora buys EyeSouth Partners' retina business for $1.1B to expand Retina Consultants of America

Cencora has signed a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion. The affiliated retina physicians will join Cencora's Retina Consultants of America, a leading management services organisation. The pharmaceutical solutions company expects the acquisition to be slightly accretive to its adjusted diluted earnings per share in the first twelve months following closure, net of financing costs. The transaction requires regulatory approvals and customary closing conditions. Cencora's reaffirmed fiscal 2026 financial guidance does not currently include the transaction closing within that fiscal year. BofA Securities served as lead financial advisor to Cencora, whilst Jefferies advised EyeSouth Partners, a portfolio company of Olympus Partners.

The Associated Press
Mar 17th, 2026
Cencora CFO James Cleary to retire after eight years, search underway for successor

Cencora has announced that Chief Financial Officer James F. Cleary will retire effective 30 June 2026. The pharmaceutical solutions company has engaged an executive search firm to identify potential successors from internal and external candidates. Cleary, 62, has served as CFO since November 2018 and joined Cencora in February 2015 following its acquisition of MWI Veterinary Supply, where he had been chief executive officer for over a decade. He will serve in an advisory capacity through the end of 2026 to ensure a smooth transition. Cencora reaffirmed its previously issued adjusted diluted earnings per share guidance range of $17.45 to $17.75 for fiscal year 2026. The company, ranked number 10 on the Fortune 500, generates more than $300 billion in annual revenue.

TradingView
Feb 11th, 2026
Cencora prices $3B senior notes offering across multiple maturities

Cencora has priced a $3 billion senior notes offering across various maturities, the company announced on 10 February 2026. No further details about the specific maturities, interest rates or intended use of proceeds were disclosed in the announcement.

Yahoo Finance
Feb 4th, 2026
Cencora raises fiscal 2026 guidance after completing OneOncology acquisition

Cencora reported 12% adjusted operating income growth and 9% adjusted diluted EPS growth in its fiscal 2026 first quarter, driven by its US healthcare solutions business. The company raised its full-year guidance to reflect year-over-year adjusted operating income growth of 11.5% to 13.5%. CEO Robert Mauch announced the completion of Cencora's acquisition of the majority remaining equity interest in OneOncology. The deal strengthens Cencora's specialty pharmaceutical leadership and MSO (management services organisation) platform. Cencora's strategy focuses on three priorities: strengthening leadership in specialty pharmaceuticals, partnering with market leaders, and enhancing patient access to pharmaceuticals. The company is leveraging technology and advanced analytics to improve customer experience and operational excellence whilst expanding its pharmaceutical-centric MSO footprint.

Yahoo Finance
Feb 4th, 2026
Cencora beats profit estimates on specialty drug demand, completes $5B OneOncology acquisition

Cencora beat Wall Street's first-quarter profit estimates on Wednesday, driven by sustained demand for specialty medicines and GLP-1 therapies. The drug distributor reported adjusted earnings of $4.08 per share, exceeding analysts' expectations of $4.04. The company completed its $5 billion acquisition of OneOncology from TPG in December, strengthening its presence in cancer care. It raised its fiscal 2026 adjusted operating income growth forecast to 11.5% to 13.5%, up from 8% to 10% previously. However, quarterly revenue of $85.93 billion fell short of expectations of $86.03 billion, sending shares down 5% in pre-market trading. Sales at its largest unit, US healthcare solutions, rose 5% year-over-year to $76.2 billion, boosted by prescription volumes of weight-loss drugs and specialty medicines.

INACTIVE